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ABSTRACT 
Chronic pain is a major global healthcare problem that is currently inadequately treated. In 
addition, the current use of opioids for treatment has reached far beyond the paucity of 
evidence for long-term benefits relative to risks. Benefit-risk models for opioid and non-
opioid treatments would benefit from a rational, mechanism-based understanding of 
neuroplastic and neurochemical contributions to chronic pain. Here we evaluate the findings 
and limitations of representative research investigating brain neuroplasticity and 
neurochemistry in chronic pain. In sum, the mechanisms of pain-related neuroplasticity in the 
brain remain poorly understood because neuroimaging studies have been largely descriptive. 
We argue that definition is needed of optimal (pain resilient) and suboptimal (pain 
vulnerable) functioning of the endogenous opioid system in order to identify neurochemical 
contributions to aberrant neuroplasticity in chronic pain. We outline the potential benefits of 
computational approaches that utilise evolutionary and statistical optimality principles, 
illustrating this approach with mechanistic hypotheses on opioid function. In particular, we 
discuss the role of predictive mechanisms in perceptual and associative plasticity and 
evidence for their modulation by endogenous opioids. Future research should attempt to 
utilise formal computational models to provide evidence for the clinical validity of this 
approach, thereby providing a rational basis for future treatment and ideally prevention.  
 
  
ABBREVIATIONS 
CS: Conditioned Stimulus 
EO: Endogenous Opioid 
fMRI: functional Magnetic Resonance Imaging  
OR: Opioid Receptor 
PAG: Periaqueductal Grey 
PC: Predictive Coding 
RL: Reinforcement Learning 
US: Unconditioned Stimulus 
 
  
INTRODUCTION: THE CHALLENGE OF CHRONIC PAIN 
Chronic pain is a major global health problem that is difficult to manage, on account of a 
number of factors: its high prevalence in the population, comorbidity (for example, with 
mental ill-health) a high degree of heterogeneity (in symptoms and causal mechanisms), and 
treatments that are largely poorly targeted to underlying mechanisms.  
Prevalence and comorbidity: The prevalence of chronic pain varies from 19% to 50% 
depending on the survey methods used and definitions of severity (Croft et al., 2010), with 
arthritis as the most common diagnosis. Increased prevalence and disproportionate disability 
has been reported in the elderly (Gunzelmann et al., 2002; Eriksen et al., 2003; Mottram et 
al., 2008), with 62% prevalence in those over 75 in the UK (Fayaz et al., 2016). One of the 
challenges we face is comorbidity with mental health problems. Chronic pain is consistently 
linked with an increased risk of depression (Breivik et al., 2013). The comorbidity of pain 
and depression is associated with a greater burden to the individual and society than either 
condition alone (Mossey and Gallagher, 2004). There has long been debate as to whether 
depression is a cause or consequence of chronic pain, but it is widely accepted that the 
presence of one will at least exacerbate the other (Bair et al., 2003). This raises the question 
as to whether the overlap between chronic pain and depression reflects a true or artificial 
comorbidity, i.e. whether there are shared biological vulnerability factors.  
Heterogeneity: Heterogeneity poses a serious challenge for research, because it introduces 
uncontrolled sources of variance, making it difficult to understand causal processes, and 
limits generalisation of results. How we select patients for research (e.g. according to 
symptoms criteria) has a bearing on generalisability. We highlight two related types of 
heterogeneity (Figure 1) which do not have a straightforward relationship. Due to symptom 
heterogeneity, many patients with chronic pain, particularly those diagnosed with arthritis, 
have a combination of recurrent acute pain and chronic ongoing pain. Indeed, in osteoarthritis 
there is a generally poor relationship between the severity of joint damage and chronic pain 
(Jordan et al., 1997; Wood et al., 2008). Even in rheumatoid arthritis, widespread pain 
unrelated to joint pathology is common (Lee and Weinblatt, 2001; Andersson et al., 2013). It 
can be argued that this is fundamentally due to mechanistic heterogeneity. Chronic pain is 
increasingly regarded as reflecting a spectrum of mechanisms including nociceptive, 
neuropathic, and central. For example, chronic ongoing pain in arthritis suggests neuropathic 
elements (Thakur et al., 2014). Chronic pain conditions in which there is very little evidence 
of nociceptive or neuropathic elements, such as atypical facial pain and chronic widespread 
pain (or fibromyalgia) have recently been termed “nociplastic” pain (from “nociceptive 
plasticity”) to reflect change in function of nociceptive pathways, probably in the central 
nervous system (Kosek et al., 2016). 
Inadequate management: In a European survey, 40% of chronic pain patients reported that 
their treatment was inadequate (Pain Proposal, 2010). For elderly people in particular, there is 
a more limited range of pain therapies available because of immobility issues, a lack of 
efficacy of pain killers (e.g. paracetamol (Roberts et al. 2015)) and/or increased side-effects 
from pain killers including non-steroidal analgesics and opiates (Shaheed et al., 2016). In the 
United States, rates of misuse, abuse and addiction to opioids (three use patterns contributing 
to the so-called “opioid epidemic”) are concerning, with misuse estimated to range from 21-
29% and addiction from 8-12% (Vowles et al., 2015). This is despite only clinically-
unimportant short-term effects on pain and function for guideline-recommended doses in 
chronic low back pain (Shaheed et al., 2016) and a complete lack of evidence for long-term 
benefits with concomitant dose-escalating serious risks (Chou et al., 2015). Decision-making 
for long-term use is currently complex and requires individual benefit-risk assessment vs. the 
relative benefits of non-opioid therapies, a judgement that is currently not evidence-based 
(Chou et al., 2015). Generally, patients report a substantial preference for non-drug therapies 
(Breivik et al., 2006). Surgical therapies for specific pathologies (e.g. brain stimulation 
(Cruccu et al., 2007)) are limited in usefulness by eligibility, while other orthopaedic 
procedures are no better than placebo or exercise (Moseley et al., 2002; Kise et al., 2016). 
Therapies focused on training the brain to deal with pain better, such as cognitive-behavioural 
therapy (Williams et al., 2012; Kong et al., 2016), hypnosis and neuro-feedback, provide low 
to moderate effects sizes but potentially long-term benefits and so further research is needed 
(Jensen et al., 2014).  
There is an urgent need to broaden the choice of safe therapies based on an understanding of 
the brain’s own powerful mechanisms of pain relief and resilience. There is also a need for 
effective predictive models of benefits and risks of different (e.g. opioid) therapies. In this 
review, we focus on the potential role of the opioid receptor (OR) system in neuroplasticity 
underlying pain vulnerability and resilience, and outline how future computational models 
have the potential to identify sub-optimal opioid function and improve patient stratification 
for treatment. 
NEUROPLASTICITY AND OPIOID FUNCTION IN CHRONIC PAIN 
BRAIN ORGANISATION IN CHRONIC PAIN 
Neuroplasticity (a change in the neuronal response after repeated experience and use), is a 
fundamental property of the whole brain (Feldman, 2009) observed in all sensory systems 
(Seitz and Dinse, 2007). Chronic pain is associated with profound changes in brain structure 
and function reflecting neuroplasticity in midbrain, thalamus and widespread regions of the 
cerebral cortex (see Table 1 for example studies). A number of different types of experience-
dependent neuroplasticity occurring in chronic pain have been observed; for example, 
changes in somatosensory cortices in Complex Regional Pain Syndrome and back pain 
(Table 1, and reviewed in detail elsewhere (Di Pietro et al., 2013; Kuner and Flor, 2016; 
Kuttikat et al., 2016)), changes in connectivity within the “default-mode network” (DMN) 
and connectivity of the DMN with descending modulatory regions (Table 1, especially Baliki 
et al., 2014; Kucyi et al., 2014) and changes in the midbrain theorised to relate to the balance 
of inhibition and facilitation in nociceptive processing in fibromyalgia (Lee et al., 2011; 
Fallon et al., 2013). However, understanding of cellular and molecular mechanisms 
contributing to central sensitisation in musculoskeletal pain conditions is largely limited to 
the spine (reviewed in (Thakur et al., 2014)). Despite a wealth of observational evidence, we 
have a very limited understanding of whether and how brain neuroplasticity might contribute 
to chronic pain symptoms and what vulnerability factors underlie this. 
While most types of pain, whether acute or chronic, tend to activate the same network of 
brain regions (Apkarian et al., 2005), there is evidence that acute experimental pain and 
clinical pain produce subtle differences in extent and amount of activation. For example, in 
patients with arthritis, clinical pain results in greater activity within prefrontal, cingulate and 
insula cortices, amygdala and putamen compared to intensity-matched experimental acute 
pain (Kulkarni et al., 2007). However, interpretation of these findings is complicated by the 
fact that many differences in pain processing are likely to be due to differences in 
psychological comorbidities. In patients with fibromyalgia, depression is associated with 
increased experimental pain responses in the amygdala and insula cortex compared to those 
without depression (Giesecke et al., 2005). More extensive differences, including greater 
prefrontal and parietal responses (Gracely et al., 2004) have been associated with high levels 
of pain catastrophising in chronic pain patients. More promisingly, functional magnetic 
resonance imaging (fMRI) studies of natural fluctuations in back pain have demonstrated 
activations of medial prefrontal cortices that appear to be quite specific to coding chronic 
pain intensity (Baliki et al., 2006, 2011). Still, the mechanisms underlying these observations 
are unknown. 
BRAIN REORGANISATION AFFECTING OPIOIDERGIC FUNCTION 
Neurochemical differences in chronic pain have been well reviewed (Tracey and Mantyh, 2007; 
Morton and Jones, 2016) and include changes in dopaminergic, opioid and GABA receptor 
systems. Evidence is consistent with the endogenous opioid (EO) system being activated 
mainly within the medial pain system during chronic pain including arthritic and neuropathic 
pain (Table 1). In chronic pain, observations of neuroplasticity within the network of brain 
regions mediating opioid-dependent analgesia point to the possibility of altered output 
properties of descending controls conferring states of pain vulnerability (Table 1). These might 
either reflect increased occupation by EOs or a fall-out of ORs. In relation to post-stroke pain, 
we favour the latter interpretation as naloxone failed to alter the pain in our study (Jones et al., 
2004) and this would also explain the requirement for higher doses of synthetic opiates in this 
type of pain (Rowbotham et al., 2003).  
Given the anatomical overlap between brain regions binding exogenous opioids and those 
undergoing neuroplasticity in chronic pain, an important consideration is whether opioid 
treatment for chronic pain is one potential driver of observed neuroplasticity. Evidence 
supporting this thesis is limited to studies of long-term opiate users showing deficits in certain 
cognition functions, namely fear-learning (Basden et al., 2016), prospective memory (Terrett 
et al., 2014) and episodic foresight (imagining the future) (Terrett et al., 2017), known to 
involve medial prefrontal interactions with basal ganglia (Peira et al., 2016) that undergo 
neuroplasticity in chronic pain (Baliki et al., 2014). While cause and effect (between opioid 
use and cognitive deficits) cannot be established from these studies, observations of changes 
in opioidergic and dopaminergic circuits and regions predicting chronic pain in the striatum 
(Baliki et al., 2012), point to the possibility that reinforcement-related changes in both brain 
plasticity and behaviour in relation to opioid use and misuse may overlap with some of the 
observations of chronic pain neuroplasticity. In relation to this it has been hypothesised that 
changes in motivational learning may be a vulnerability factor for chronic pain (Mansour et al., 
2014).  
Pain vulnerability resulting from neuroplasticity in the opioid system could be countered by 
physiologically enhancing pain resilience. One possibility is to inhibit the breakdown of 
endogenous opioids with inhibitors of natural enkephalinases in the brain (Le et al., 2003). 
Another possibility is increasing OR density through yet-to-be-discovered mechanisms. Indeed, 
our recent study of patients with arthritis (Brown et al., 2015) suggest that variability in OR 
density is a natural aspect of endogenous pain regulation. In particular, patients with greater 
recent clinical pain had greater OR binding (consistent with greater OR density) in the striatum, 
thalamus, insula and periaqueductal grey (PAG). Evidence for this being a possible mechanism 
of pain resilience is that binding in the striatum (caudate nucleus) was also correlated positively 
with acute pain threshold in both patients with arthritis and normal pain-free volunteers. The 
mechanism by which this occurs is not clear but one possibility is that delta OR agonism (as a 
result of EO release in response to pain) upregulates mu-ORs in humans as it has been shown 
to in animals (Wang et al., 1999; Cahill et al., 2001; Morinville et al., 2003).  
Cognitive or lifestyle interventions may be able to enhance EO mechanisms; for example, 
exercise in normal volunteers enhances activity of the EO system in prefrontal, cingulate and 
insula cortices (Boecker et al., 2008), but with unknown effects on OR density. However, the 
rational use of such interventions for the purposes of enhancing opioid-dependent pain 
resilience is limited by a current lack of mechanistic understanding of the function of the EO 
system in the brain. 
INVESTIGATING PAIN AND OPIOID MECHANISMS WITH 
NEUROIMAGING 
Understanding the role of neuroplasticity and opioid function in chronic pain vulnerability 
requires a mechanistic understanding of pain processing in the brain. Until the mid-20th century, 
pain perception was thought to be a direct reflection of the afferent processes of nociception - 
pain processing in the brain was considered unidirectional and passively received by a single 
brain centre (Melzack and Wall, 1965). However, after the introduction of the ‘pain matrix’ 
theory (Melzack and Wall, 1965), the concept of pain evolved towards active, multidirectional 
and multicentre cognitive information processing. More recently, the concept of pain-specific 
cognitive and emotional networks has been replaced with a view of shared brain functions 
involved with processing pain as well as other motivationally salient stimuli (Legrain et al., 
2011), although it seems likely that pain is likely to be a construct of a specific pattern of 
activity within this network (Wager et al., 2013). Furthermore, cognitive and emotional 
processing takes an active role in the endogenous modulation of pain (see Table 1). 
Observations such as these contribute towards our understanding of mechanistic heterogeneity 
in chronic pain, particularly with regard to understanding individual differences in the efficacy 
of endogenous pain control, a common factor thought to affect many types of chronic pain 
(Staud, 2012).  
  
BOX 1: CHALLENGES IN UNDERSTANDING THE MECHANISMS OF PAIN VULNERABILITY 
AND RESILIENCE 
Research question: Investigating a biological mechanism requires asking the right research question. 
Neuroimaging studies have been largely descriptive, i.e. seeking to answer the question of what the 
brain (including the opioid system) does in response to (or in prediction of) acute and chronic pain, and 
cognitive and affective modulation of pain. Such descriptions provide useful data for classification, 
prediction, and for the generation of hypotheses and models, but are unable to test hypotheses to answer 
why and how; for example, why and how does neuroplasticity in opioidergic brain regions contribute to 
chronic pain? In other words, we currently lack a comprehensive process theory for the functional role 
of the opioid system in pain perception and chronic pain vulnerability. Research questions seeking to 
identify such a theory would help to integrate descriptive research findings and provide greater utility in 
inform us about what treatments may be appropriate under certain contexts.  
Sample selection: Research normally seeks to answer questions in specific populations, involving the 
selection of recruitment criteria to sample the right patients. Most commonly, selection relies on 
diagnostic categories and symptom profiles. However, such categories lack predictive clinical validity 
(e.g. in predicting the outcome of certain treatments), because diagnostic heterogeneity does not 
currently map on to mechanistic heterogeneity. This means that we cannot distinguish whether 
descriptive observations of brain abnormalities in a patient group defined by diagnostic category (e.g. 
osteoarthritis) are due to a unique biological pathology, a psychological comorbidity (that nonetheless 
has more complex biological substrates), or a difference in cognitive strategy or emotional response to 
the experiment, for example patient anxiety at being in an MRI scanner. 
Design and methodology: While appropriate research design largely follows from the research question 
and sample, some general considerations are outlined here. Methodological challenges arise from a 
number of factors including arranging for the subject to be in an appropriate pain state, practical or 
technological limitations in measuring the target physiological processes, limitations in the number of 
variables/factors that can be investigated within a single study, and a lack of standardisation of how 
neuroimaging data are acquired, making it difficult (but not impossible) to compare and combine data 
across sites and studies. More longitudinal studies are also required to establish which brain responses 
are associative and which causal in relation to pain vulnerability. Future work will benefit from efforts 
to standardise and share neuroimaging data, enabling larger-scale and more highly powered research, 
necessary for longitudinal research and some of the more complex designs (Table 1). 
However, the majority of neuroimaging studies of cognitive and emotional influences on pain 
have been conducted using experimental pain stimuli in healthy people (Table 1). Furthermore, 
studies are generally descriptive rather than providing evidence of mechanisms underlying 
cognitive and emotional influences on pain. Hence, whilst functional brain imaging has made 
a major contribution to our understanding of pain physiology and pathophysiology over the 
past few decades, we are still barely scratching the surface of understanding the fundamental 
mechanisms underlying chronic pain vulnerability. 
We identify three main challenges (Box 1): identifying the correct research question, 
selecting the appropriate participant samples for study, and designing/implementing the 
appropriate experimental methodology (e.g. Table 1). Here we focus on the first challenge: 
identifying the right research question. Descriptive approaches (asking “what” questions) 
frequently do not provide insight into the causal mechanistic processes that explain 
observations. By contrast, normative approaches are explicit about the hypothesised function 
of a system, for example, considering what problem is being solved or goal of the system and 
how this might be optimally achieved (Niv, 2009), thereby providing a basis for 
understanding and identifying sub-optimal function. Normative approaches commonly refer 
to the evolutionary principle that the purpose of organisms is to provide optimal or near-
optimal adaption to the (physical and social) environment (Kacelnik, 1997). In this regard, 
the function of the brain can be thought of as optimising perception and behaviour through 
learning processes. This provides the ability to generate and direct test computationally 
explicit hypotheses about the function of brain systems (Niv, 2009), including 
neurotransmitters such as opioids, in terms of how they optimise perception and behaviour 
through learning. 
Evolutionary pressures have hard-wired brain systems towards adaptation through processes 
that maximise reward (e.g. food, mating opportunities, money, knowledge) and minimise 
punishment (e.g. pain, hunger, social rejection). These processes can sometimes be related, 
such that failure to acquire reward is punishing (Tom et al., 2007), and avoiding a punishment 
or relieving pain is rewarding (Navratilova and Porreca, 2014). In this case, there is a 
cooperative opposition in the pain and reward systems (Leknes and Tracey, 2008), which has 
been linked to activity in the striatum consistent with dopamine signalling during associative 
learning tasks (Seymour et al., 2005, also see Box 2). Likewise, maximising longer-term 
rewards may require suppressing short-term pain, for example when reaching limits of 
physical endurance during exercise in which the long-term goal is greater physical fitness. In 
this case, opioidergic activity in the striatum may be important suggested by endorphin 
release during exercise (Boecker et al., 2008). These reward-pain motivational interactions 
have been conceptualised by Fields (2006) according to a motivation-decision model, in 
which neural decision-making is based on the predicted homeostatic value to the organism of 
each option. Current reinforcement learning (RL) models (see Box 2) require theoretical 
advances to account for how the value of certain actions can be approximated when rewards 
depend on the long-term consequences of those actions (Gershman and Daw, 2017). These 
more advanced RL models are likely to enable a more complete understanding of the 
cooperation between dopaminergic and opioidergic signalling in the basal ganglia.  
In parallel, the specific function of endogenous opioids in the brain requires further 
elaboration. Evidence summarised in Figure 2 challenges the assumption that opioids only 
mediate antinociceptive responses, suggesting rather that opioids modulate nociception bi-
directionally via the basal ganglia and insula, converging on a common midbrain descending 
pathway. An alternative hypothesis of opioid function is called for to account for these 
considerations. A promising candidate that we will explore in the following sections (see also 
Figure 2) is that the opioid system within the basal ganglia and midbrain functions to 
optimise predictions about pain, consistent with striatal functions in learning predictions of 
reward value and that of the amygdala and anterior insula in learning predictions of aversive 
value. Testing this hypothesis will require models of the explicit neural computations 
involved. 
  
  
BOX 2: COMPUTATIONAL MODELS OF LEARNING AND PERCEPTION 
Computational neuroscience uses normative principles to understand explicit mechanisms of brain 
function. A common approach, inspired from David Marr’s influential work (Marr, 1982), is to (1) 
define the computational optimisation problem (i.e. identify the problem the brain is trying to solve 
and its underlying principles), (2) identify a range of potential process models / algorithms (i.e. what 
representations and operations are required in the brain to solve the problem), and (3) constrain the 
repertoire of process models with reference to biological observations (i.e. how do neurons carry out 
the algorithm to achieve the computational goal?). A successful example is that of reinforcement 
learning (RL). Originally popularised by Rescorla and Wagner (Rescorla and Wagner, 1972), RL 
models formalise how associative learning occurs. The optimisation problem, maximising future 
reward, is solved by learning the value of environmental cues according to an algorithm in which 
organisms are “surprised” (generate a prediction error) when events violate expectations. Prediction 
errors have been equated to the motivational salience of environmental cues that provide information 
about rewards (Berridge, 2007). Critically, empirical evidence supports RL models in that both 
reward and aversive prediction errors are closely related to phasic activation of the ventral striatum 
consistent with dopaminergic signalling (O’Doherty et al., 2003; Seymour et al., 2004).  
While RL provides a compelling model of reward and aversive learning, it does not provide a model 
for pain-related neuroplasticity in sensory pain networks. An important consideration is that in order 
to optimally learn and adapt to the environment, the brain needs to make perceptual decisions (e.g. 
“Is this painful or not?”; “Is this situation dangerous?”) as well as behavioural decisions (e.g. 
avoidance or approach). This leads to the question of how the brain deals with the uncertainty, a 
major topic of research in the neurosciences (for a review, see Bach and Dolan, 2012). Sources of 
uncertainty in sensory perception include neuronal noise and incomplete/ambiguous information, 
meaning that there are many possible states of the world that could give rise to any one sensory input 
(Friston, 2003). This leads naturally to the idea that perception is a process of unconscious, statistical 
inference (the “Bayesian brain” hypothesis), which to be optimal requires that the brain represents 
sensory information in the form of probability distributions (with variance indicating uncertainty) 
(Friston, 2003). However, there is debate as to whether the brain can actually perform such 
computations due to the problem of bounded rationality which recognises cognitive processing 
capacity limitations available to the brain (Gershman et al., 2015). Recent computational theories of 
perceptual inference borrow theoretic principles from statistical physics and information theory to 
solve this problem by assuming that the optimality principle the brain uses for sensory perception is 
to minimise free-energy, or the upper bound on the surprise (entropy) of the sensory states it 
experiences (Friston et al., 2006). This principle converts intractable Bayesian inference into a 
neuronally computable optimisation problem.  
 
BAYESIAN MODELS OF PAIN NEUROPLASTICITY 
Computational neuroscience has provided normative models for how the brain might 
optimise perception and behaviour (Box 2), with many approaches converging on the view 
that the brain applies statistical inference to sensory inputs in order to resolve uncertainty. 
How this is implemented in the brain is an active topic of research. A leading framework is 
that of predictive coding (PC), which provides a biologically plausible scheme based on 
simple rules of synaptic plasticity (Hebbian learning) (Bogacz, 2015). PC models assume that 
learned knowledge (implicit or explicit) about the world is represented hierarchically as a set 
of ‘priors’, which capture the statistical regularities of brain activity (reflecting environmental 
regularities) at lower levels to resolve sensory uncertainty.  
Predictive coding provides an attractive framework to account for the modulation of pain by 
learning processes such as those underlying placebo and nocebo effects (Büchel et al., 2014) 
commonly attributed to the endogenous opioid system. We and others (Edwards et al., 2012; 
Kuttikat et al., 2016) have also suggested that PC is an appealing approach to understand 
functional and potentially subsequent structural plasticity occurring in chronic pain. 
According to the Bayesian optimality principle, pain experience would depend on the extent 
of the mismatch between the learnt predictions and current sensory inputs, but also on their 
relative ‘precision’ weights, reflecting the uncertainty of the representation. Precision weights 
are thought to be learnt over a lifetime (Bogacz, 2015), thus providing stable or slowly 
changing traits. This may be particularly important in chronic pain conditions associated with 
psychological trauma in childhood and early adulthood (Gupta et al., 2007). However, to 
date, there has been no investigation of whether the PC framework provides an explanation 
for neuroplastic changes in chronic pain.  
Our experimental observations in healthy individuals and chronic pain patients have, 
however, provided some general support for a Bayesian account of pain vulnerability. If the 
brain uses a Bayesian updating scheme for pain perception, at least three phenomena would 
need to occur: firstly, that the brain predicts nociceptive inputs; secondly, that the brain 
models the uncertainty (inverse precision) of those predictions; thirdly, that greater precision 
(certainty) in predictions more greatly biases pain perception in the direction of those 
predictions. Our and others research measuring anticipatory brain responses has indeed 
discovered that neural processes prior to the experience of pain predict the subsequent 
nociceptive input and serve as the basis for the modulation of pain perception by expectations 
(Brown et al., 2008a, 2008b; Atlas et al., 2010). Furthermore, we have shown that subjective 
confidence (as a metacognitive representation of Bayesian precision (Meyniel et al., 2015)) in 
predictions is related to the extent to which expectations influence pain perception and is 
related to activity in the anterior insula cortex (Brown et al., 2008b), a region through which 
expectancy effects are mediated (Atlas et al., 2010). While this research does not directly test 
a Bayesian model or a predictive coding scheme for pain perception, it does point to the 
importance of predictive processes in acute pain and is consistent with Bayesian optimality 
principles. Furthermore, predictive processing appear to have relevance to chronic pain: In 
patients with fibromyalgia, the anterior and posterior insula are over-active when anticipating 
pain, while anticipatory posterior insula activity predicts pain symptoms in patients with 
fibromyalgia as well as those with osteoarthritis (Brown et al., 2014).  
However, despite recent interest in the Bayesian and predictive coding framework for acute 
pain, knowledge is currently limited on how these principles pertain to the situation of 
chronic pain. Very little work has been done in computational modelling of chronic pain 
symptoms and behaviour. Such models may provide the ability to test the recent hypothesis 
(derived from descriptive longitudinal studies of chronic pain neuroplasticity (Mansour et al., 
2014)) that the value and saliency of both nociceptive and rewarding stimuli are altered in 
those vulnerable to chronic pain. In important first step in this direction will be to test for the 
construct validity of predictive coding models in chronic pain, i.e. do they effectively account 
for individual variability, and variability over time, in pain-related neuroplasticity in the 
brain? In addition, the validity of generative computational models (such as predictive 
coding) would rest on their ability to account for how symptoms can arise from underlying 
hidden mechanisms. A second step required is clinical validation, for example do such 
models have predictive validity for future pain symptoms and/or treatment outcomes? If so, 
once other hurdles (such as test-retest reliability of different models) have been overcome, the 
clinical potential is substantial. By inferring mechanisms rather than relying on symptom 
profiles, the approach may finally achieve the lofty ambition of mechanism-based 
stratification for treatment. 
OPIOID FUNCTION IN PAIN VULNERABILITY AND RESILIENCE 
We argue the need to better understand the precise function in the brain of the opioid system in 
a normative sense. This will provide a definition of optimal and suboptimal functioning to 
facilitate diagnosis and treatment. A view of the brain’s predictive mechanisms provide insights 
into the role of the EO system in chronic pain vulnerability and resilience. 
EOs have been intensively studied for their role in the modulation of nociception. Many 
nociceptive forebrain areas are rich in ORs (mu, delta and kappa) and modulated by EOs, 
including the frontal cortices, anterior cingulate and midcingulate cortices, the thalamus, 
striatum, insula, hypothalamus and central nucleus of the amygdala. Opiate drugs and EOs act 
on ORs in these regions to produce analgesia (Jones et al., 1991; Petrovic et al., 2002; Zubieta 
et al., 2005; Eippert et al., 2009). However, evidence suggests that the actions of EOs is partly 
to mediate or reinforce neural predictions. For example, placebo analgesia, thought to be 
mediated by conscious or unconscious (e.g. conditioned) expectations (Watson et al., 2012), is 
opioid-mediated (Benedetti et al., 2005). Furthermore, behavioural and neuroimaging studies 
show that the analgesic effect of synthetic opiates during experimental pain is blocked by 
negative suggestion (Bingel et al., 2011). This highlights a potentially important interaction 
between opioids and predictive mechanisms in the brain. 
Further evidence from Pavlovian fear conditioning experiments suggests that endogenous 
opioids may specifically optimise predictions about pain to promote associative learning. In 
rodents, when a neutral conditioned stimulus (CS) was repeatedly paired with an 
unconditioned stimulus (US, a painful shock) and over time came to predict that shock, 
endogenous opioids were released resulting in analgesia (Fanselow and Baackes, 1982). The 
effect was blocked with opioid antagonism (e.g. naloxone), which in addition facilitated 
learning of the CS-US pairing, in rats (Bolles and Fanselow, 1982; McNally et al., 2004) and 
humans (Eippert et al., 2008). However, a series of experiments (McNally et al., 2004) 
involving blocking designs discovered that opioid enhancement of fear learning is not due to 
a greater US (i.e. increased pain) from opioid antagonism, but rather results from a specific 
increase in the prediction error learning signal (the discrepancy between the US and CS). 
Further observations were that over the course of fear conditioning, the CS increasingly 
resulted in EO signalling in the ventrolateral PAG, which acted to limit further fear learning 
(McNally and Cole, 2006). In addition, EO signals act to not only limit fear learning, but also 
fear extinction (McNally, 2009). These observations are consistent with OR activity encoding 
the prediction (i.e. the CS) rather than the painful outcome (i.e. the US), as the latter would 
result in the opposite to the observed extinction learning behaviour (McNally, 2009). In other 
words, EOs appear to be important for learning the prediction, i.e. the transfer of information 
from the US to the prior CS over time. Buchel et al., in discussing predictive mechanisms of 
placebo (Büchel et al., 2014), speculate that opioidergic signalling specifically represents the 
precision of predictions, consistent with Bayesian updating scheme for pain perception. 
However, whether there is a pain vulnerability mechanism involving altered opioid signalling 
during the encoding or expression of predictions of pain is a hypothesis that remains to be 
tested.  
CONCLUSIONS 
The brain is best considered as an active participant in shaping the sensory-perceptual and 
cognitive/emotional aspects of pain. In chronic pain, observations of neuroplasticity within 
the network of brain regions mediating opioid-dependent analgesia may confer states of pain 
vulnerability, but the meanings of such observations have proved challenging to interpret in 
light of the potential for a range of influences on these regions such as from nociceptive 
inputs, cognitive and behavioural strategies, and long-term use of opiate analgesics. 
Computational models that use normative optimality principles may help to make sense of 
pain-related pathophysiology in individuals with chronic pain. Evidence currently supports 
(but does not explicitly test) the hypothesis that endogenous opioids function to optimise 
predictions about pain to serve adaptive perception and behaviour. Further research is 
required to test whether opioids directly modulate prediction per se or act on the precision of 
predictions according to a Bayesian updating scheme. Identification of these mechanisms, 
requiring psychopharmacology experiments in combination with computational modelling, 
will serve to provide a definition of sub-optimal opioid system functioning and a rational 
basis for chronic pain prevention and treatment. 
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FIGURE 1  
 
Two types of clinical heterogeneity. Due to symptom heterogeneity, many patients with 
chronic pain have a combination of recurrent acute pain and chronic ongoing pain, variable 
evidence of tissue damage and differences in cognitive and mood symptoms. The underlying 
mechanistic heterogeneity reflects variability in nociceptive, inflammatory, neuropathic, and 
central mechanisms. 
FIGURE 2  
 
Opioidergic modulation of motivational learning processes play a role in the contextual 
modulation of pain. For illustrative purposes, the schematic simplifies the main opioid-
mediated top-down pathways involved in the modulation of nociception by internal (e.g. 
beliefs, mood, distress) and external (e.g. placebo treatment) context. Further bottom-up and 
recurrent pathways exist but are not illustrated for clarity and were recently reviewed 
elsewhere (Büchel et al., 2014; Navratilova and Porreca, 2014).  
A) Many cortical systems potentially mediate phenomena such as placebo hypoalgesia 
(Büchel et al., 2014), but all likely originate within the prefrontal cortex and it’s 
interactions with the perigenual ACC as evidenced by their activation during 
anticipation of pain and prediction of placebo analgesia (Wager et al., 2004, 2011). 
This regions, through interactions with limbic areas, provide contextual cognitive 
information critical to the learning of reward and aversive value information 
(reviewed in Navratilova and Porreca, 2014). This is consistent with observations of 
abnormal vStr activity being a potential vulnerability factor in chronic pain (Purple 
inset, Baliki et al., 2012). SBPp: Subacute back pain, persistent. SBPr: Subacute back 
pain recovered.  
B) AIns-Amyg form a circuit required for fear learning (Critchley et al., 2002) that 
shows opioid release during placebo analgesia (Zubieta et al., 2005). While anterior 
insula is deactivated during placebo analgesia (Price et al., 2008), it mediates the 
effects of negative expectations on increased pain (Brown et al., 2008b; Atlas et al., 
2010) and shows abnormal anticipatory processing in patients with chronic pain (Red 
inset, Brown et al., 2014). 
C) A role for opioiderigic activity in vStr in setting nociceptive sensitivity/salience is 
evidenced by bidirectional modulation of vStr attenuating or enhancing nociception 
(Gear and Levine, 2011) which depends on upstream ACC opioid circuits 
(Navratilova et al., 2015). Consistent with this, pain thresholds in chronic pain 
patients correlate with opioid receptor availability in vStr (Green inset, Brown et al., 
2015) presenting a potential vulnerability/resilience factor. 
D) The cortical and subcortical projections all converge onto the PAG-RVM-spinal cord 
system which either inhibits or facilitates nociception (Fields, 2004). 
  
TABLE 1: 
Research methodologies and example results in the neuroimaging of pain.  
Pain induction 
method 
Within-subject 
comparisons 
Between-
subject/group 
comparisons  
Mixed 
comparisons 
1. Experimental 
pain induction 
Modulation of pain 
processing by:  
Cognitive distraction 
(e.g. Bantick et al., 
2002). 
Expectation (e.g. Lorenz 
et al., 2005; Brown et al., 
2008a; Atlas et al., 2010) 
Hypnotic analgesia (e.g. 
Rainville et al., 1999; 
Huber et al., 2013) 
Placebo treatments (e.g. 
Wager et al., 2004; 
Watson et al., 2009). 
Mindfulness meditation 
(e.g. Brown and Jones, 
2010; Zeidan et al., 
2011). 
Endogenous opioid 
function (Zubieta et al., 
2001; Sprenger et al., 
2006). 
Cerebral pain 
processing affected 
by individual 
differences in pain 
catastrophising 
(e.g. Gracely et al., 
2004; Michael and 
Burns, 2004; 
Brown et al., 2014; 
Loggia et al., 
2015), fear and 
anxiety (e.g. 
Ochsner et al., 
2006) and altered 
sleep (Petrov et al., 
2015). 
Studies are needed 
to investigate the 
moderator effects of 
between-subjects 
characteristics (e.g. 
pain 
catastrophising) on 
within-subject 
contextual 
modulation of pain 
(e.g. attention, 
expectation and 
placebo effects).  
2. Chronic pain 
presence / 
absence or 
induction / 
suppression 
Reductions opioid 
receptor binding within 
the medial pain system in 
patients with post-stroke 
pain (Jones et al., 1999) 
Reduced opioid 
receptor binding in 
fibromyalgia vs. 
controls (Harris et 
al., 2007), post-
stroke pain vs 
Future research 
could investigate (1) 
interactions between 
psychological 
factors (e.g. pain 
catastrophising) and 
and arthritic pain (Jones 
et al., 1994). 
Fluctuations in chronic 
low back pain correlating 
with functional 
connectivity of medial 
prefrontal cortex with 
other brain regions 
(Baliki et al., 2011). 
controls (Willoch 
et al., 2004) and 
central vs 
peripheral 
neuropathic pain 
(Maarrawi et al., 
2007). 
Changes in resting-
state functional 
networks between 
chronic pain 
conditions and 
controls (Baliki et 
al., 2014; Kucyi et 
al., 2014; Fallon et 
al., 2016)  
changes in opioid 
receptor binding in 
response to chronic 
pain, (2) how 
patients with 
different patterns of 
network 
connectivity in the 
brain differ in 
endogenous opioid 
system functioning. 
3. Chronic pain 
vs. acute pain 
 
Greater processing in the 
medial pain system for 
chronic arthritic vs. acute 
pain (Kulkarni et al., 
2007; Parks et al., 2011).  
N/A – requires 
within-subject 
comparisons 
Future studies could 
investigate whether 
differential medial 
pain system activity 
in chronic vs. acute 
pain is related to 
levels of 
psychological 
distress. 
4. Chronic pain 
natural history 
or treatment 
response 
Structural brain changes 
from of arthroplasty in 
osteoarthritis (Gwilym et 
al., 2010). 
Differences in brain 
function and structure in 
subacute vs. chronic pain 
N/A – requires 
within-subject 
comparisons 
Identifying patient 
subgroups with 
different prospective 
outcomes from 
baseline brain 
structure/function 
(e.g. Baliki et al., 
2012). 
stages of low back pain 
(e.g. Baliki et al., 2012). 
Changes in 
somatosensory cortical 
reorganisation with 
recovery in patients with 
Complex Regional Pain 
Syndrome (Maihöfner et 
al., 2004). 
Changes in prefrontal 
cortex structure or 
function with cognitive-
behavioural therapy (e.g. 
Seminowicz et al., 2013; 
Čeko et al., 2015)  or 
mindfulness meditation 
(e.g. Brown and Jones, 
2013). 
Studies are required 
to identify 
predictors of 
response to 
difference 
treatments, e.g. 
cognitive-
behavioural therapy, 
analgesics, physical 
therapies. 
 
Footnote: Studies can be broadly categorised into (1) those that use a standardised acute or 
tonic pain stimulus to understand different aspects of pain processing, (2) studies where 
patients are scanned in different clinical pain states, (3) where responses are compared 
between standardised experimental pain and clinical pain, (4) longitudinal observations of 
changes in pain processing according to naturalistic changes or treatment-related changes. 
Furthermore, in each case, studies can make within-subject, between subject or mixed 
comparisons. Examples are provided of studies within each category where possible. Studies 
further down and/or to the right side of the table generally require greater sophistication and 
resources, and are therefore less common, but provide greater mechanistic insights into 
chronic pain vulnerability. 
